Answers are grounded in this paper and cite their sources.
This study illustrates the potential of ctDNA as a biomarker for detecting minimal residual disease and recurrence in HNSCC and demonstrates the feasibility of personalised ctDNA assays for the detection of disease prior to clinical recurrence.
No takes yet. Share an insight, caveat, or question.
Flach et al. (2022) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: